Similar expression profiles in CD34(+) cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib

The life expectancy of patients with chronic phase chronic myeloid leukemia on tyrosine kinase inhibitor therapy now approaches that of the general population. Approximately 60% of patients treated with second generation tyrosine kinase inhibitors achieve a deep molecular response, the prerequisite...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Patel, Ami B., Lange, Thoralf, Pomicter, Anthony D., Conley, Christopher J., Harrington, Christina A., Reynolds, Kimberly R., Kelley, Todd W., O’Hare, Thomas, Deininger, Michael W.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2018
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5915162/
https://ncbi.nlm.nih.gov/pubmed/29707154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24954
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki